Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Acute Myeloid Leukemia Refractory: early-phase trial registry
11 of 13 indexed Acute Myeloid Leukemia Refractory trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,315 of 28,707 conditions by registered trial count.
13 US clinical trials · 11 currently recruiting · #1,315 of 28,707 conditions by registered trial count
Acute Myeloid Leukemia Refractory: 13 US clinical trials tracked, 11 recruiting.
Acute Myeloid Leukemia Refractory is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 11 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 2 of these trials.
Enrollment posture brief
Registry condition acute-myeloid-leukemia-refractory
OPEN 11 | RECR 85% | LATE 0 | EARLY 13 | RANK #1315 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Blood Cancer (85% recruiting · 13 trials)
Acute Myeloid Leukemia Refractory lists 11 open slots (85% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Acute Myeloid Leukemia Refractory on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Acute Myeloid Leukemia Refractory is recruiting above its size-band peers.
11 of 13 indexed trials (84.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Acute Myeloid Leukemia Refractory research.
Memorial Sloan Kettering Cancer Center accounts for 2 of 13 trials (15.4%). 12 distinct sponsors appear on at least one study for this condition label.
-
Most Acute Myeloid Leukemia Refractory trials plan to enrol fewer than 100 people.
Median target enrolment is 38 among the 13 trials that report a genuine target (sentinel values excluded). 12 of those (92.3%) plan for fewer than 100 participants.
-
Acute Myeloid Leukemia Refractory research is mostly interventional.
13 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
13 total, page 1 of 1
Study of REM-422 in Patients With AML or Higher Risk MDS
Remix Therapeutics
NCT06297941
AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
AB Science
NCT05211570
Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)
Oryzon Genomics S.A.
NCT05546580
Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
ARCE Therapeutics
NCT06680752
A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
Bio-Path Holdings
NCT05190471
Venetoclax to Augment Epigenetic Modification and Chemotherapy
Medical College of Wisconsin
NCT05317403
Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)
University of Illinois at Chicago
NCT06802315
A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia
Memorial Sloan Kettering Cancer Center
NCT07011004
PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML
Seattle Children's Hospital
NCT05105152
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
Memorial Sloan Kettering Cancer Center
NCT06017258
Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Keystone Nano
NCT04716452
Lentivirally Redirected CD123 Autologous T Cells in AML
University of Pennsylvania
NCT03766126
KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia
University of Colorado, Denver
NCT04914845
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 12 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Acute Myeloid Leukemia Refractory records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Acute Myeloid Leukemia Refractory trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Acute Myeloid Leukemia Refractory page
13 registered trials, 11 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 11 Acute Myeloid Leukemia Refractory trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Acute Myeloid Leukemia Refractory trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Acute Myeloid Leukemia Refractory condition card totals 13 registered trials; most-linked intervention Fludarabine; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.